** Shares of Compass Therapeutics CMPX.O down 5.3% post-market to $3.00 after equity raise news
** Boston, Massachusetts-based oncology-focused biopharma launches offering of stock and pre-funded warrants; deal size not disclosed
** Co intends to use net proceeds to conduct initial preparations for commercial readiness, to fund R&D, clinical development of its product candidates, among other purposes
** Jefferies, Piper Sandler and Guggenheim are joint active bookrunners for the offering
** Co has ~138.3 mln shares outstanding for ~$440 mln market cap, per LSEG data
** CMPX shares on Tues finished down 5.1% at $3.17
** Stock gained ~24% on Mon after co reported Q2 results and provided data on its pipeline
** Avg rating among 10 analysts is "strongbuy" and median PT is $10.50 - LSEG
** Shares ended 2024 at $1.45
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。